Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Five million doses of Prevtec Microbia’s bivalent vaccine Coliprotec® F4/F18 Sold in the European Union


Posted on: 03 May 18

MONTREAL, May 03, 2018 (GLOBE NEWSWIRE) -- Prevtec Microbia Inc. (“Prevtec”) is pleased to announce that five million doses of its bivalent vaccine Coliprotec® F4/F18 have been sold in the European Union (EU) since its commercial market authorization in 2017.

The product is a live bacterial vaccine containing a combination of two non-pathogenic E. coli strains for active immunization of pigs against post-weaning diarrhea (PWD) caused by E. coli. It is given orally to pigs as a single dose either as a drench or by addition to drinking water.

The European Medicines Agency (EMA) considers Coliprotec F4/F18 to have the potential to change the current practice to give antibiotics to control infection in pig herds.(1) On 27 July 2016, the EMA recommended that colistin-containing medicines should only be used as a second line treatment in animals and that their sales should be minimized (reduction of 65%) across all EU Member States to reduce the risk of antimicrobial resistance. The advice updates EMA guidance from 2013 and takes into account a decision to withdraw the marketing authorizations (MAs) for veterinary medicines containing zinc oxide administered orally to food producing species. Member states have been given up to five years, from the date of adoption of the Commission Decision, to withdraw existing national MAs for these products. Colistin and zinc oxide are both widely used across the EU to control PWD.

“The bivalent vaccine developed by Prevtec Microbia and distributed by Elanco in the EU and in Canada is a great innovation which meets our customers’ needs. This sales threshold of five million doses is significant and we plan to bring this product to the next level in the coming years”, said Dr. Ralph Heuser, Elanco Vice President Operations, Europe, Middle East & Africa.

Michel Fortin, President and CEO of Prevtec added: “We are proud of our swine vaccine portfolio and the achievement of this sales milestone. Post-weaning diarrhea caused by E. coli has a negative effect on animals’ well-being and can cause major economic losses in pig production. We are demonstrating, with great success, that our product is an alternative to antibiotics to improve animal health in the European Union and in Canada with the support of our distribution partner Elanco.”

(1) Veterinary Medicines Highlights / www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/01/WC500220067 

About Prevtec Microbia

Prevtec Microbia is a Canadian biotechnology company developing and commercializing sustainable solutions as alternatives to antibiotics to improve animal health, production performance and food safety. Prevtec Microbia’s first commercial product, Coliprotec®F4, a swine E. coli vaccine, has been sold across Canada since 2007 and in the EU since 2015, and is approved in Brazil (2010) and in the US (2018). In early 2017, marketing authorizations were granted for Coliprotec® F4/F18 in the EU and Canada and, thereafter in Russia and the CIS countries. The Coliprotec® line of vaccines is completed with Coliprotec® F18, distributed in Canada since 2015. See more information at www.prevtecmicrobia.com.

Sources:
  
Michel Fortin Nicole Blanchard 
President and CEO  Sun International Communications 
+1 514 905-0401 +1 450 973-6600
mfortin@prevtecmicrobia.comnicole.blanchard@isuncomm.com           
GlobeNewswire
globenewswire.com

Last updated on: 03/05/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.